Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the company, which has filed over a dozen patents, has been granted their second in relation to its proprietary cannabidiol formulations around the hard pill format.
Goldstein telling Proactive what this means for the company and he also said the company plans to prove greater bio-availability through a blood level study at a third party Clinical Research Organization that is currently in the planning stages.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE